Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes AI

The Future of Longevity: AI and Nanorobots to Radically Extend Life

by Team Lumida
June 25, 2024
in AI, Health and Longevity
Reading Time: 3 mins read
A A
0
person holding black and white microscope

Photo by Jaron Nix on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

  1. AI-driven drug discovery could drastically cut down clinical trial times.
  2. Medical nanorobots may revolutionize immune systems by the 2030s.
  3. By 2040s, mind-backup systems might allow near-immortality.

What Happened?

Futurist Ray Kurzweil claims that AI will revolutionize drug discovery and medical interventions by the end of the 2020s. He believes biological simulators will soon generate crucial safety and efficacy data in hours, not years.

This shift could lead to faster drug approvals and save countless lives. Kurzweil also predicts that medical nanorobots will emerge in the 2030s, vastly enhancing our immune systems and treating metabolic diseases. By 2040s, he envisions mind-backup systems that could essentially render death obsolete.

Why It Matters?

These advancements could disrupt traditional medical models and extend human lifespans dramatically. Faster drug approvals would mean quicker access to lifesaving treatments. Medical nanorobots could address diseases that our natural immune systems can’t, such as cancer and neurodegenerative disorders.

The potential to back up our minds might lead to radical life extension, fundamentally changing the concept of mortality. Investors should note the profound implications for the healthcare and biotech sectors, which could experience exponential growth.

What’s Next?

Expect increased investment in AI-driven pharmaceutical research and biotech firms focused on nanotechnology. Regulatory landscapes will evolve to accommodate simulated trials, despite potential bureaucratic resistance. By the mid-2040s, mind-backup technologies will likely face ethical and security challenges, but Kurzweil is optimistic about overcoming these hurdles.

As these technologies become mainstream, they will likely follow the trajectory of the cell phone—starting expensive and exclusive, but eventually becoming widely accessible.

Source: Fortune Well
Tags: AI-driven drug discoverymedical nanorobotsmind-backup systemsRay Kurzweil
Previous Post

Bitcoin Crashes to $62K: What’s Behind the $150M Liquidation?

Next Post

TikTok Ban Could Dent Oracle’s Earnings: What Investors Need to Know

Recommended For You

Microsoft Rejects Option to More Than Double Its Texas Nscale Deal, Dealing a Blow Ahead of the AI Start-Up’s Planned $35 Billion IPO

by Team Lumida
2 hours ago
Microsoft’s AI Ambitions: A Costly Path Forward

Microsoft turned down an option to expand its Texas compute contract with Nscale, pressuring the Nvidia-backed start-up’s $35 billion IPO plans.

Read more

Election-Day Revolt Against Data Centers Puts More Than 40% of Planned U.S. Capacity in Play as CoreWeave Slides Nearly 10%

by Team Lumida
2 hours ago
Blackstone and Brookfield Lose Major Virginia Data Center Project After Civil War Preservationist Lawsuit

Voters backed anti-data-center candidates and local bans, putting Texas, Georgia and Ohio AI buildouts at risk.

Read more

Meta’s President Says New U.S. Data Centers Will Be “Very Challenging” After the Midterms, Even as Capex Runs Toward $145 Billion

by Team Lumida
2 hours ago

Meta’s president said starting new U.S. data centers will be very challenging after the midterms, while expanding existing sites looks easier.

Read more

Oracle Scraps a $7 Billion, 100,000-Chip AI Lease With Tencent After US Officials Raise Concerns, as Washington Squeezes Cloud Providers Serving Chinese AI

by Team Lumida
1 day ago

Oracle cancelled a roughly $7 billion deal to lease up to 100,000 AI chips to Tencent after US officials raised concerns, the FT reported.

Read more

Hinojosa’s Texas Win Hits the AI Trade as CoreWeave Falls 7% and Democrats Now Govern States Holding About 44% of Planned US Data Center Capacity

by Team Lumida
1 day ago
Blackstone and Brookfield Lose Major Virginia Data Center Project After Civil War Preservationist Lawsuit

AI stocks fell overnight after Democrat Gina Hinojosa, who backs a data center moratorium, won the Texas governor’s race, a state with 27% of planned capacity.

Read more

Anthropic’s IPO Investors Push for a More Cautious $1.5 Trillion to $1.6 Trillion Valuation After Last Week’s Tech Rout, Well Below $2 Trillion Talk

by Team Lumida
2 days ago
Anthropic Tells Investors It Will Post a Second Straight Profitable Quarter Ahead of Nasdaq IPO

Big investors are pushing Anthropic toward a $1.5T-$1.6T IPO valuation, below earlier $2T talk, after the tech rout, WSJ reports.

Read more

Nvidia Orders Data Center Partners to Sell at Least 51% of Their Services to Non-Chinese Customers, Tightening the Squeeze on China’s AI Ambitions

by Team Lumida
2 days ago
How Nvidia’s AI Chips are Secretly Making Their Way to China

Nvidia told cloud partners to sell at least 51% of services to non-Chinese firms, the FT reports, as a rack of B300 chips fetches $2.8M in China.

Read more

Blackstone’s Jon Gray Says the AI Buildout Needs More Equity as Lenders Pile Up Concentration Risk, While Pimco’s CEO Warns $10 Trillion of Capex Could Prove ‘Too Much’

by Team Lumida
2 days ago

Blackstone’s Jon Gray says AI infrastructure needs more equity as debt risks mount, while Pimco’s CEO warns $10T of AI capex could be too much for markets.

Read more

Goldman Sachs Bars Most Traders and Bankers From AI Coding Tools Like Claude Code and GitHub, Limiting Them to Engineers After Reviewing Productivity and Risk

by Team Lumida
3 days ago
Goldman’s Big Bet on Wealth Lending: Doubling Down on the Ultra-Rich

Goldman Sachs has limited AI coding tools like Anthropic’s Claude Code and Microsoft’s GitHub to engineers, frustrating some traders who had used them.

Read more

Anthropic’s Revised S-1 Shows $17 Billion in Third-Quarter Revenue but a Swing to a $567 Million Operating Loss, Plus $895.4 Billion in Compute Commitments

by Team Lumida
3 days ago

Anthropic’s amended S-1 shows $17B in Q3 revenue, a $567M operating loss as compute costs jumped, and $895.4B in compute and lease commitments.

Read more
Next Post
a red cube with white text

TikTok Ban Could Dent Oracle's Earnings: What Investors Need to Know

a person holding a phone

AI and Crypto Shakeup: Nvidia and Bitcoin's Massive Drops Explained

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Tech Titans Pivot: Silicon Valley’s New Alliance in Trump’s Second Term

Trump Sets a 15% Growth Bar for Fed Pick Warsh, Raising Independence Stakes

February 10, 2026
blue coupe parked beside white wall

Tesla’s Record Valuation Faces Reality Check as EV Sales Drop for First Time

January 3, 2025
Global Markets Mixed as Nvidia News Boosts Futures, While Inflation and Trade Tensions Loom

Global Markets Mixed as Nvidia News Boosts Futures, While Inflation and Trade Tensions Loom

July 15, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018